Christina Maria Duzyj, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta Accreta | 7 | 2023 | 242 | 1.950 |
Why?
|
| Trophoblasts | 4 | 2018 | 223 | 1.400 |
Why?
|
| Postpartum Hemorrhage | 3 | 2022 | 275 | 1.290 |
Why?
|
| Obstetrics | 3 | 2022 | 681 | 0.970 |
Why?
|
| Cesarean Section | 9 | 2023 | 1425 | 0.800 |
Why?
|
| Placenta Previa | 3 | 2023 | 125 | 0.560 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2018 | 254 | 0.550 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 519 | 0.510 |
Why?
|
| Placenta | 6 | 2023 | 1725 | 0.500 |
Why?
|
| Patient Care Team | 2 | 2022 | 2523 | 0.450 |
Why?
|
| Ultrasonography, Prenatal | 4 | 2023 | 1772 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7454 | 0.420 |
Why?
|
| Pregnancy | 23 | 2023 | 30256 | 0.360 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 1656 | 0.360 |
Why?
|
| Cadherins | 1 | 2015 | 905 | 0.350 |
Why?
|
| Biological Factors | 1 | 2010 | 156 | 0.330 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 3929 | 0.310 |
Why?
|
| Decidua | 2 | 2018 | 82 | 0.290 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1883 | 0.280 |
Why?
|
| Maternal Age | 2 | 2019 | 805 | 0.260 |
Why?
|
| Myometrium | 2 | 2018 | 174 | 0.260 |
Why?
|
| Delivery, Obstetric | 3 | 2022 | 954 | 0.220 |
Why?
|
| Hypothermia | 1 | 2024 | 189 | 0.210 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2020 | 14 | 0.180 |
Why?
|
| Surge Capacity | 1 | 2020 | 49 | 0.170 |
Why?
|
| Uterine Balloon Tamponade | 1 | 2020 | 37 | 0.170 |
Why?
|
| Pandemics | 1 | 2020 | 8748 | 0.170 |
Why?
|
| Premature Birth | 4 | 2019 | 1829 | 0.160 |
Why?
|
| Hysterectomy | 3 | 2023 | 863 | 0.160 |
Why?
|
| Uterine Cervical Diseases | 1 | 2019 | 75 | 0.160 |
Why?
|
| Cervical Length Measurement | 1 | 2019 | 47 | 0.160 |
Why?
|
| Chorionic Villi Sampling | 1 | 2018 | 35 | 0.160 |
Why?
|
| Amniocentesis | 1 | 2018 | 116 | 0.150 |
Why?
|
| Term Birth | 1 | 2019 | 140 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 862 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2020 | 540 | 0.140 |
Why?
|
| Placentation | 1 | 2017 | 78 | 0.140 |
Why?
|
| Puerperal Disorders | 1 | 2019 | 304 | 0.130 |
Why?
|
| Gestational Age | 3 | 2024 | 3621 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 500 | 0.130 |
Why?
|
| Female | 25 | 2024 | 397192 | 0.130 |
Why?
|
| Keratin-7 | 1 | 2015 | 55 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2019 | 577 | 0.120 |
Why?
|
| Embryo Implantation | 1 | 2017 | 272 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2024 | 2124 | 0.120 |
Why?
|
| Vimentin | 1 | 2015 | 257 | 0.110 |
Why?
|
| Betamethasone | 1 | 2014 | 48 | 0.110 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 529 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2015 | 242 | 0.110 |
Why?
|
| Cell Movement | 2 | 2018 | 5210 | 0.100 |
Why?
|
| Pregnancy Outcome | 2 | 2023 | 2972 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2017 | 812 | 0.100 |
Why?
|
| Stillbirth | 1 | 2015 | 381 | 0.100 |
Why?
|
| Parturition | 1 | 2015 | 455 | 0.090 |
Why?
|
| Inhibins | 1 | 2011 | 210 | 0.090 |
Why?
|
| Presenilin-1 | 1 | 2015 | 666 | 0.090 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 616 | 0.090 |
Why?
|
| Risk Factors | 5 | 2020 | 74944 | 0.090 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2011 | 137 | 0.090 |
Why?
|
| Humans | 26 | 2024 | 768166 | 0.090 |
Why?
|
| Activins | 1 | 2011 | 211 | 0.090 |
Why?
|
| Retrospective Studies | 9 | 2023 | 81762 | 0.090 |
Why?
|
| beta Catenin | 1 | 2015 | 1047 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2020 | 2235 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2024 | 3857 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3573 | 0.080 |
Why?
|
| Adult | 12 | 2022 | 223646 | 0.070 |
Why?
|
| Pregnancy, Ectopic | 1 | 2009 | 145 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 697 | 0.070 |
Why?
|
| Pregnancy Trimester, First | 1 | 2010 | 917 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 26379 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 1892 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2973 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2019 | 3288 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2020 | 4852 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 1255 | 0.060 |
Why?
|
| Delivery Rooms | 1 | 2024 | 38 | 0.060 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2009 | 587 | 0.060 |
Why?
|
| Superantigens | 1 | 2003 | 124 | 0.050 |
Why?
|
| Antigens, Heterophile | 1 | 2003 | 71 | 0.050 |
Why?
|
| Cicatrix | 1 | 2009 | 798 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3109 | 0.050 |
Why?
|
| Body Temperature Regulation | 1 | 2024 | 292 | 0.050 |
Why?
|
| Smoking | 1 | 2019 | 9092 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3463 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 2185 | 0.040 |
Why?
|
| Fetal Distress | 1 | 2019 | 39 | 0.040 |
Why?
|
| Gravidity | 1 | 2019 | 50 | 0.040 |
Why?
|
| Intrauterine Devices | 1 | 2020 | 115 | 0.040 |
Why?
|
| Dystocia | 1 | 2019 | 36 | 0.040 |
Why?
|
| Breech Presentation | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 7453 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 2024 | 712 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7876 | 0.040 |
Why?
|
| Obesity | 1 | 2019 | 13090 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2019 | 9669 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2010 | 19015 | 0.030 |
Why?
|
| International Agencies | 1 | 2017 | 244 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 737 | 0.030 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2019 | 468 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2017 | 223 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 2393 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2017 | 454 | 0.030 |
Why?
|
| Placenta Diseases | 1 | 2017 | 199 | 0.030 |
Why?
|
| Logistic Models | 2 | 2019 | 13290 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2024 | 26422 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2014 | 3228 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 556 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 2014 | 296 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 5505 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2019 | 1198 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 1275 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 1561 | 0.020 |
Why?
|
| Recurrence | 1 | 2023 | 8509 | 0.020 |
Why?
|
| Propensity Score | 1 | 2019 | 1969 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 4415 | 0.020 |
Why?
|
| Immunoassay | 1 | 2014 | 746 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 2011 | 268 | 0.020 |
Why?
|
| Cell Communication | 1 | 2017 | 1660 | 0.020 |
Why?
|
| Vital Statistics | 1 | 2009 | 31 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 2011 | 381 | 0.020 |
Why?
|
| Apgar Score | 1 | 2009 | 126 | 0.020 |
Why?
|
| Hospitals, Private | 1 | 2009 | 67 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 15948 | 0.020 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2009 | 65 | 0.020 |
Why?
|
| Uterine Artery Embolization | 1 | 2009 | 62 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 704 | 0.020 |
Why?
|
| United States | 4 | 2019 | 73039 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2009 | 204 | 0.020 |
Why?
|
| Uterine Hemorrhage | 1 | 2009 | 236 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2009 | 458 | 0.020 |
Why?
|
| New York City | 1 | 2009 | 737 | 0.020 |
Why?
|
| Young Adult | 3 | 2019 | 60066 | 0.020 |
Why?
|
| Incidence | 1 | 2024 | 21538 | 0.020 |
Why?
|
| Hospitals | 1 | 2019 | 3886 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6229 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7852 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 2167 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2019 | 9384 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2056 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2019 | 8080 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2020 | 54926 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18412 | 0.010 |
Why?
|
| Methotrexate | 1 | 2009 | 1721 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15869 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13671 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2003 | 381 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 3858 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2003 | 366 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20227 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2020 | 65371 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2003 | 1340 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 1441 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2014 | 8543 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24315 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 2295 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2009 | 2517 | 0.010 |
Why?
|
| Adolescent | 2 | 2019 | 89169 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41754 | 0.010 |
Why?
|
| Medicaid | 1 | 2009 | 2840 | 0.010 |
Why?
|
| Aorta | 1 | 2003 | 2045 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 6231 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 5995 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 4427 | 0.010 |
Why?
|
| Animals | 2 | 2017 | 169246 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 4648 | 0.010 |
Why?
|
| Male | 1 | 2024 | 364719 | 0.000 |
Why?
|
| Middle Aged | 1 | 2019 | 223492 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 22379 | 0.000 |
Why?
|
| Mice | 1 | 2003 | 82029 | 0.000 |
Why?
|